FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2740784411> ?p ?o ?g. }

• W2740784411 abstract "Glioblastoma (GBM) is a World Health Organization grade IV astrocytoma with poor patient survival, characterized by extreme heterogeneity and invasiveness, and by resistance to radiation and chemotherapeutic drugs. Brain metastases are 2-3x more frequent than GBM, with breast cancer among the top 3 brain metastasizing tumor types. The tumor suppressor phosphatase and tensin homolog on chromosome ten (PTEN) is mutated or deleted in ~50% of all high grade gliomas and is lost in 33-49% of all breast cancers. We propose to target the dysregulated PTEN pathway in brain tumors to enhance patient survival. Oncolytic viruses are engineered to destroy tumor cells while sparing non-neoplastic cells, and can be designed to incorporate payloads that enhance their oncolytic effects. PTEN-L is a recently discovered, longer form of PTEN which is secreted and membrane permeable, and retains its phosphatase activity after secretion and re-entry into cells. We have generated a novel oncolytic herpesvirus (RAPTOR) that secretes PTEN-L from infected cells for the treatment of GBM and breast cancer brain metastases (BCBM). In vitro assays to evaluate virally mediated tumor cell killing, virus replication, transgene expression, and flow cytometry to evaluate intracellular pAkt and cell surface programmed death ligand 1 (PD-L1) were performed. In vivo studies using mice bearing orthotopic human GBM (nude mice) or murine BCBM (nude and FVB/N) were used to evaluate brain immune infiltrates and survival. Western blot analyses of infected cell lysates and conditioned media show that RAPTOR produces functional secreted PTEN-L, as confirmed by intracellular pAkt FACS. Tumor cell killing and replication were equivalent between RAPTOR and control HSVQ. In vivo, treatment of mice bearing established orthotopic BCBM revealed improved anti-tumor efficacy of RAPTOR. Significantly, 9/10 RAPTOR treated mice were long term survivors in immunocompetent FVB/N mice vs. 4/10 HSVQ treated mice (p=0.044). Treatment of nude mice bearing the same tumors did not produce long term survivors, implicating the development of antitumor immunity in RAPTOR treated animals. Flow cytometry revealed significant down regulation of the T-cell repressor PD-L1 on RAPTOR vs. HSVQ treated cells. Consistent with this, FACS of virus treated tumor bearing brain hemispheres revealed RAPTOR induced a significant influx in antigen presenting, NK, and CD8 T cells 7 days post treatment. Our findings demonstrate that RAPTOR enhances survival of brain tumor bearing mice using a two-pronged approach: lytic tumor cell death and immune cell education and activation against the brain tumor. RAPTOR inhibits virally induced PD-L1 expression on tumor cells, and could pave the way for a paradigm shift in immune therapy where immune checkpoint inhibition occurs locally within the tumor rather than globally, overriding toxicity of neutralizing antibodies. Citation Format: Luke Russell, Alexander Sprague, Alena Cristina Jaime-Ramirez, Chelsea Bolyard, Yeshavanth Banasavadi-Siddegowda, JiYoung Yoo, Pin Yi Wang, Timothy Cripe, Balveen Kaur. Oncolytic and immune effects of RAPTOR: a novel oncolytic Herpes Simplex Virus 1 expressing PTEN-L for brain tumor therapy [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2017; 2017 Apr 1-5; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2017;77(13 Suppl):Abstract nr 601. doi:10.1158/1538-7445.AM2017-601" @default.
• W2740784411 created "2017-08-08" @default.
• W2740784411 creator A5015870107 @default.
• W2740784411 creator A5017250643 @default.
• W2740784411 creator A5035017270 @default.
• W2740784411 creator A5041131555 @default.
• W2740784411 creator A5058531555 @default.
• W2740784411 creator A5064769954 @default.
• W2740784411 creator A5076596743 @default.
• W2740784411 creator A5080599250 @default.
• W2740784411 creator A5080897550 @default.
• W2740784411 date "2017-07-01" @default.
• W2740784411 modified "2023-09-26" @default.
• W2740784411 title "Abstract 601: Oncolytic and immune effects of RAPTOR: a novel oncolytic Herpes Simplex Virus 1 expressing PTEN-L for brain tumor therapy" @default.
• W2740784411 doi "https://doi.org/10.1158/1538-7445.am2017-601" @default.
• W2740784411 hasPublicationYear "2017" @default.
• W2740784411 type Work @default.
• W2740784411 sameAs 2740784411 @default.
• W2740784411 citedByCount "0" @default.
• W2740784411 crossrefType "proceedings-article" @default.
• W2740784411 hasAuthorship W2740784411A5015870107 @default.
• W2740784411 hasAuthorship W2740784411A5017250643 @default.
• W2740784411 hasAuthorship W2740784411A5035017270 @default.
• W2740784411 hasAuthorship W2740784411A5041131555 @default.
• W2740784411 hasAuthorship W2740784411A5058531555 @default.
• W2740784411 hasAuthorship W2740784411A5064769954 @default.
• W2740784411 hasAuthorship W2740784411A5076596743 @default.
• W2740784411 hasAuthorship W2740784411A5080599250 @default.
• W2740784411 hasAuthorship W2740784411A5080897550 @default.
• W2740784411 hasConcept C121608353 @default.
• W2740784411 hasConcept C2777609662 @default.
• W2740784411 hasConcept C2779549131 @default.
• W2740784411 hasConcept C3020616263 @default.
• W2740784411 hasConcept C502942594 @default.
• W2740784411 hasConcept C530470458 @default.
• W2740784411 hasConcept C54355233 @default.
• W2740784411 hasConcept C62478195 @default.
• W2740784411 hasConcept C82210918 @default.
• W2740784411 hasConcept C86554907 @default.
• W2740784411 hasConcept C86803240 @default.
• W2740784411 hasConcept C95444343 @default.
• W2740784411 hasConceptScore W2740784411C121608353 @default.
• W2740784411 hasConceptScore W2740784411C2777609662 @default.
• W2740784411 hasConceptScore W2740784411C2779549131 @default.
• W2740784411 hasConceptScore W2740784411C3020616263 @default.
• W2740784411 hasConceptScore W2740784411C502942594 @default.
• W2740784411 hasConceptScore W2740784411C530470458 @default.
• W2740784411 hasConceptScore W2740784411C54355233 @default.
• W2740784411 hasConceptScore W2740784411C62478195 @default.
• W2740784411 hasConceptScore W2740784411C82210918 @default.
• W2740784411 hasConceptScore W2740784411C86554907 @default.
• W2740784411 hasConceptScore W2740784411C86803240 @default.
• W2740784411 hasConceptScore W2740784411C95444343 @default.
• W2740784411 hasLocation W27407844111 @default.
• W2740784411 hasOpenAccess W2740784411 @default.
• W2740784411 hasPrimaryLocation W27407844111 @default.
• W2740784411 hasRelatedWork W1485753978 @default.
• W2740784411 hasRelatedWork W2011357184 @default.
• W2740784411 hasRelatedWork W2032262403 @default.
• W2740784411 hasRelatedWork W2058660954 @default.
• W2740784411 hasRelatedWork W2084379257 @default.
• W2740784411 hasRelatedWork W2100303734 @default.
• W2740784411 hasRelatedWork W2121028233 @default.
• W2740784411 hasRelatedWork W2144434005 @default.
• W2740784411 hasRelatedWork W2158375335 @default.
• W2740784411 hasRelatedWork W2295866100 @default.
• W2740784411 hasRelatedWork W2331962566 @default.
• W2740784411 hasRelatedWork W2776551433 @default.
• W2740784411 hasRelatedWork W2778994189 @default.
• W2740784411 hasRelatedWork W2953479904 @default.
• W2740784411 hasRelatedWork W2954128362 @default.
• W2740784411 hasRelatedWork W3013506418 @default.
• W2740784411 hasRelatedWork W3082390126 @default.
• W2740784411 hasRelatedWork W3157722999 @default.
• W2740784411 hasRelatedWork W3191034723 @default.
• W2740784411 hasRelatedWork W3202579497 @default.
• W2740784411 isParatext "false" @default.
• W2740784411 isRetracted "false" @default.
• W2740784411 magId "2740784411" @default.
• W2740784411 workType "article" @default.